| Code | CSB-RA896903MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to NNC0491-6075, targeting angiopoietin-like protein 3 (ANGPTL3). ANGPTL3 is a liver-secreted glycoprotein that inhibits lipoprotein lipase and endothelial lipase, thereby regulating plasma triglyceride and HDL cholesterol levels. Loss-of-function mutations in ANGPTL3 are associated with familial combined hypolipidemia and reduced cardiovascular disease risk, while elevated ANGPTL3 levels contribute to dyslipidemia and atherosclerosis. This makes ANGPTL3 a compelling therapeutic target for managing lipid disorders and preventing cardiovascular events.
NNC0491-6075, developed by Novo Nordisk, is an investigational monoclonal antibody designed to neutralize ANGPTL3 function and lower lipid levels in patients with refractory hypercholesterolemia and hypertriglyceridemia. This biosimilar antibody serves as a valuable research tool for investigating ANGPTL3 biology, lipid metabolism pathways, and cardiovascular disease mechanisms. It enables studies examining the therapeutic potential of ANGPTL3 inhibition and supports the development of novel lipid-lowering strategies.
There are currently no reviews for this product.